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Introduction
Long-term follow-up studies have indicated that women who undergo treatment for cervical intra-epithelial neoplasia grade 2 or 3 (CIN2/3) have an increased long term risk of recurrent CIN2 lesions or worse (≥rCIN2) compared to the general population.
1,2
Because of this long-term risk, gynecologists in many countries use surveillance strategies in order to detect recurrent disease. These surveillance strategies vary greatly in content and length. In many Western countries, women are monitored by cervical cytology at six, 12 and 24 months after treatment, and are referred to the routine screening program after three subsequent negative scrapes. 3 . Recently, it has been shown that the addition of high-risk human papillomavirus (hrHPV) DNA testing to cytology at six months after treatment dramatically increases the sensitivity for ≥rCIN2. 2, 4 When at six months both test results are negative, testing at 12 months can be omitted without an increased ≥rCIN2 risk. 2 Recurrent CIN2/3 lesions are known to represent a group of heterogeneous diseases, comprising persistent lesions resulting from residual (i.e.
incompletely treated) disease with persistence of the same HPV genotype, and incident (i.e. early onset) lesions. Incident lesions can either result from an infection with a hrHPV type different from the original type in the resected CIN2/3 lesion (incident rCIN), or a re-infection with the same hrHPV type as the original one. 5 Morphologically, persistent rCIN2/3 lesions cannot be distinguished from incident counterparts, and all rCIN2/3 are therefore treated. This may lead to overtreatment, which is (especially) harmful for women in their reproductive age since it may lead to adverse pregnancy outcomes. 6 For a more tailored management of women diagnosed with recurrent disease, studies on biomarkers that can detect women in immediate need of re-treatment are warranted.
Ideally these biomarkers should distinguish persistent rCIN2/3 lesions, with likely a high short-progression risk to cancer (so-called advanced lesions) and therefore in need of immediate treatment, from incident, so-called early rCIN2/3 lesions, with a likely low short-term progression risk to cancer and for which a more conservative approach is acceptable. Potential biomarker tests that can discriminate between early and advanced stages of cervical disease involve tests assessing DNA promoter methylation of certain host cell tumor suppressor genes involved in cervical carcinogenesis. [7] [8] [9] [10] Cell adhesion molecule1 (CADM1) and myelin and lymphocyte (MAL) belong to the most frequently methylated genes in cervical carcinoma. 8, 11 Silencing of these genes by DNA promoter methylation is a common and functionally relevant event in cervical cancer development. [12] [13] [14] We have previously shown that the extent of DNA promoter methylation of CADM1 and MAL genes increases with the severity of cervical disease and that these epigenetic changes are considered to reflect the presence of a more advanced highgrade CIN lesion with a longer duration of existence. 9, 11, 15 This is supported by the finding that levels of CADM1 and MAL promoter methylation are extremely high in cervical cancer and signifi cantly increased in CIN3 lesions of women with a hrHPV infection that has persisted over a long time period (≥5 years) compared to early onset CIN3 lesions resulting from a recently acquired hrHPV infection. 7 In this study, we have evaluated the performance of CADM1/MAL-methylation analysis as a potential tool to monitor women treated for CIN2/3 for recurrent disease.
Methods and materials Study population
This study was designed as a multicenter prospective clinical cohort study conducted in six outpatient clinics in The Netherlands. The study fl owchart is depicted in Fig. 7 or an adenocarcinoma in situ (AIS) lesion was confi rmed in the LLETZ specimen (seeand-treat), were enrolled. The study was approved by the Medical Ethical Committee (METC) of the VU medical center (METC-VUmc 2009/285) and endorsed by all other participating clinics and registered in The Netherlands Trial Register (NTR1964). All women gave written informed consent prior to any study procedure.
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Thinprep medium and analyzed in the reference laboratory for cytology, hrHPV presence and methylation status. After taking the cervical scrape, an exit-colposcopy with mandatory biopsy was also performed at this 12 month visit. Primary outcome measure was ≥rCIN3 and ≥rCIN2. 
No biopsy n=10
*a: At baseline, a cervical scrape was taken previous to the LLETZ for hrHPV and methylation marker testing.
*b: At six months post-treatment, a cervical scrape was taken previous to the biopsy for cytology, hrhPV and methylation marker testing.
Cytology reading
The Dutch CISOE-A classification was used to report the cytological results. Quantitative methylation-specific PCR (qMSP)
Isolated DNA was modified by bisulfite treatment using the EZ DNA Modification Kit (Zymo Research, Baseclear, Leiden, The Netherlands) as described previously. 13 Quantitative Methylation Specific PCR (qMSP) analysis for CADM1 and MAL was performed on an ABI 7500 real-time PCR-system (Applied Biosystems, USA) as described previously, using β-actin (ACTB) as a reference. 19 All qMSP assays were run in separate reactions.
Cycle threshold (Ct) values were measured at a fixed fluorescence threshold (i.e., 0.01).
Ct ratios between the Ct values of the β-actin and target were used to quantify the level of methylation, as calculated by the following formula: 2[Ct (β-actin) − Ct (target)] × 100. Ct signals of N40 were considered to represent a negative test result, whereas samples with Ct values for β-actin that were higher than 32 were considered invalid and therefore excluded from analysis because of an indication of poor DNA quality or poor recovery after bisulfite treatment. 19 The CADM1 and MAL qMSP Ct ratio thresholds that were used to score the CADM1/MAL-methylation test positive were those that in a previous study gave rise to a ≥CIN3 specificity of ≥70%. 19 The CADM1/MAL-methylation test is considered positive if either one or both markers score positive.
Colposcopic examination
During colposcopic assessment, biopsies were taken from all suspicious areas. In case no suspicious lesion was seen, or if the transformation zone could not be fully visualized (in which the colposcopy was considered 'unsatisfactory'), a biopsy from a random location and/or endocervical curettage was performed. An exit-colposcopy was performed at the last study visit in all subjects to exclude any histological abnormalities. Histological specimens were graded as CIN grade 0 (no dysplasia), 1, 2, 3, or invasive cancer. 20 For the purpose of this study AIS was counted as CIN3.
Study outcomes
Women reached the primary study-endpoint when they had ≥rCIN2 in the biopsy specimen taken during colposcopy at six months post-treatment or at the exit-colposcopy at 12 months. Women who developed recurrent disease rCIN2/3) were re-treated by re-LLETZ or conisation and followed-up according to present guidelines. 3 In January 2014,
we verified follow-up data of all women with post-treatment disease from local hospital databases. When histology results from re-treatment (either re-LLETZ or conisation)
were available, these were taken as secondary endpoint.
Statistical analysis
The sample size was set at 360 assuming that 10% of treated women would present with ≥rCIN2, and taking 5% drop out into account.
Cross-sectional analysis
The association between hrHPV status, CADM1/MAL-methylation status, and histology groups (LLETZ result at baseline) was assessed using the χ2C-test. Also for assessing the association between cytology, hrHPV, CADM1/MAL-methylation, and the risk for ≥rCIN3 and ≥rCIN2, the χ2-test was used.
Longitudinal analysis
For comparisons between the CADM1/MAL-methylation results at baseline and histological outcome of recurrent disease, we used the study endpoint of ≥rCIN2 at six or 12
months. For evaluation of the methylation status over six and 12 months in relation to the study endpoint we used the results of the scrape taken directly prior to the 
Cross-sectional analysis

Baseline results
From eight of 364 women no cervical scrape prior to treatment was available, resulting in 356 women with a hrHPV and/or CADM1/MAL-methylation marker test result at baseline ( 
Six months post-treatment
Six months post-treatment, 364 women were supposed to have their first follow-up visit. those who had no biopsy taken, were followed up at 12 months.
Of the 11 women without histology, one was scored as adjusted ≤CIN1 endpoint given a cytology-negative and hrHPV-negative cervical scrape, and 10 as 'no endpoint', resulting in 340 women for 6-month cross-sectional analysis ( 
Twelve months post-treatment
At six months post-treatment 22 women reached study ≥rCIN2 endpoint, leaving 342
women who were supposed to have their second follow-up visit at 12 months posttreatment. Nineteen of them did not show up at 12 months, five were pregnant, two emigrated, one deceased and three underwent a hysterectomy. Of the resulting 312 evaluable women, all but ten women received colposcopy including an exit biopsy. At six months post-treatment, 14 women from the 364 included did not show up. In 11 women with one or more positive test results no biopsy was taken, of whom one had an adjusted endpoint ≤CIN1. This resulted in 340 cases available for analysis.
c At 12 months post-treatment, from the 342 women eligible for follow up 30 women did not show up. In ten women no exit biopsy was taken, of whom seven had adjusted endpoint ≤CIN1. Moreover, in one women, an exit-biopsy was taken, but no cervical scrape. This resulted in 308 cases available for analysis.
Histology revealed 282 ≤ CIN1, 13 CIN2 and seven CIN3. Of the ten women without histology, seven were scored as adjusted ≤CIN1 endpoint given a cytology-negative and hrHPV-negative cervical scrape, and three as 'no endpoint'. Moreover, one woman with rCIN2 had a protocol violation: only an exit biopsy was taken without a cervical scrape. Valid test results (either cytology, hrHPV and/or methylation marker testing)
were available from 308 women.
At 12 months post-treatment a positive test result for either cytology, hrHPV or CADM1/ MAL-methylation was associated with a significantly increased risk of ≥rCIN2 in the exit-biopsy ( 
Longitudinal analysis
Recurrent CIN lesions
Over a period of in total 12 months follow-up, 28 CIN2 lesions (7.7%) and 14 CIN3 lesions (3.8%) were detected in this post-treatment cohort, amounting to a CIN2/3 recurrence rate of 11.5%. Of the 28 women with rCIN2 in their biopsies, the re-LLETZ specimen contained ≤CIN1 in 18 women (64%), CIN2 in two (7%), CIN3 in four (14%).
Four women (14%) did not undergo a re-LLETZ but had a cervical scrape read as BMD at follow-up (no endpoint). Of the 14 women with rCIN3 biopsies, the re-LLETZ specimen contained ≤CIN1 in five women (36%), CIN2 in three (21%), CIN3 in three (21%) and three women had SCC of the cervix (21%). The relation between the methylation status on the scrapes taken prior to biopsy and histology results is shown in Table 7 .2. CADM1/ MAL-methylation negative scrapes often yielded a ≤CIN1 lesion (75%) in the re-LLETZ tissue. Furthermore, all three cervical carcinomas found in the re-LLETZ were preceded by a CADM1/MAL-methylation positive scrape.
Incident versus persistent infections
In Table 7 .3 the methylation marker status in rCIN2, rCIN3 and in the overall rCIN group, stratified according to HPV genotype-switch in follow-up to define incident or persistent infection is shown. Of all rCIN2 lesions, five showed an incident infection with type switch and 15 revealed a persistent infection. All rCIN3 lesions showed type persistence. Of women with persistent infections, 9/14 rCIN3 (64%) and 8/15 rCIN2 (53%) were CADM1/MAL-methylation positive. All five recurrent lesions with incident infections were CADM1/MAL-methylation negative. The relationship between hrHPV type in rCIN2/3 and the CADM1/MAL-methylation status is depicted in Supplementary Table   7 .2.
Pre-and post-treatment methylation marker status
For longitudinal analysis, the methylation status at baseline was combined with methylation status at follow-up and related to the risk of ≥rCIN3 and ≥rCIN2 ( Table 7 .4).
Compared to methylation marker negative test results at both baseline and follow-up, methylation positivity at both baseline and follow-up significantly increased the risk of ≥rCIN3 from 0.7% to 18.4%, and for ≥rCIN2 from 8.2% to 36.8% (p-values < 0.001).
Furthermore, within the group of women with a positive CADM1/MAL-methylation test at baseline, the ≥rCIN3 risk was significantly higher for those that were CADM1/ MAL-methylation positive at follow-up (18.4%) compared to those that were CADM1/ MAL-methylation negative at follow-up (3.7%, p-value < 0.007). The same figures were seen for ≥ rCIN2 (i.e., 36.8% versus 6.4%, p-value < 0.001). 
Discussion
Various studies have analyzed the use of methylation markers as triage tool for HPVpositive women in cervical cancer screening. [8] [9] [10] However, to the best of our knowledge the use of a methylation marker analysis for post-treatment monitoring has not been evaluated before.
In this study, we evaluated the performance of CADM1/MAL-methylation analysis for monitoring women treated for high-grade CIN. We assessed the cross-sectional and longitudinal performance, and the relationship with persistence of recurrent disease using persistent HPV infections as a surrogate marker. The rCIN2/3 percentage of 11.5% after 12 months follow-up is in agreement with previous studies. 1,2 All 14 rCIN3 were associated with a persistent hrHPV infection, and nine thereof (64%) were CADM1/MALmethylation positive. Of 28 rCIN2 lesions, at least five were incident lesions as evidenced by a hrHPV type-switch, and these were all negative for CADM1/MAL-methylation.
Of the 15 rCIN2 with a persistent hrHPV infection, eight (53%) were positive for CADM1/ MAL-methylation. CADM1/MAL-methylation was found significantly associated with severity of disease in this cohort of women treated for CIN2/3. Moreover, cross-sectionally, a positive CADM1/MAL-methylation test result at baseline, six months or 12 months post-treatment was associated with an increased risk of ≥rCIN3 and ≥rCIN2. In the longitudinal analysis, a positive CADM1/MAL-methylation test at baseline and in follow-up 
